Highest-materiality recent filing
Chris Hyder named EVP & COO effective June 17; base salary $800k, STI target 100%, $4M RSU grant (3-yr vest).
Clorox CEO Linda Rendle steps down for health reasons; board initiates search
Rendle will remain Chair and CEO during the search and until the new CEO is appointed.
Clorox issues $1.5B of senior notes in three tranches maturing 2031-2036
$550M of 4.700% Senior Notes due 2031 issued.
Clorox Q3 net sales flat at $1.67B; adj. EPS +13% to $1.64; gross margin down 140bps
Diluted EPS $1.54 (+3% YoY); adjusted EPS $1.64 (+13% YoY) on cost savings and lower ad spend.
Clorox completes acquisition of GOJO Industries (Purell) – expands health & hygiene portfolio
Clorox closed purchase of all membership interests of GOJO Industries, maker of Purell.
Clorox enters $2.25B credit facilities to fund GOJO (PURELL) acquisition
Entered $1B 364-day revolver and $1.25B delayed draw term loan on March 6, 2026, both unsecured and unguaranteed.
Clorox Q2 FY2026 sales down 1% to $1.67B, EPS $1.29, reaffirms outlook
Net sales $1.67B (-1% YoY); organic sales -1%; gross margin 43.2% (-60 bps).
Clorox to acquire GOJO Industries (Purell) for $2.25B cash; net $1.92B after tax benefits
Purchase price $2.25B, including ~$330M tax benefits, net $1.92B; expected close before end of FY2026.
Clorox shareholders elect all director nominees, approve say-on-pay and auditor ratification
All 11 director nominees elected with majority support; Linda Rendle received 81.2M for, 6.6M against (92.4% for).
Clorox Q1 FY2026: Net sales down 19% to $1.43B, adj. EPS $0.85 (-54% YoY) on ERP disruption
Diluted EPS $0.65 vs $0.80 prior year; adjusted EPS $0.85 vs $1.86 (-54%), largely due to ERP transition.
Clorox EVP & COO Eric Reynolds resigns after 27 years; no replacement planned
Eric Reynolds, EVP – Chief Operating and Strategy Officer, resigns after 27 years at Clorox.
Clorox Q4 adj EPS $2.87 (+58% YoY); organic sales +8% on ERP pull-forward; provides FY26 outlook
Q4 net sales $2.0B (+4% GAAP, +8% organic); incremental ERP shipments contributed ~13-14 points to sales.
Clorox amends bylaws to add cure process for shareholder nomination deficiencies
Board adopted amended bylaws effective May 19, 2025.
Clorox Elects Gina Boswell, CEO of Bath & Body Works, to Board
Election effective May 19, 2025; Boswell will join Nominating, Governance & Corporate Responsibility Committee.
Clorox Q3 sales fall 8% to $1.67B; adjusted EPS down 15% to $1.45; outlook cautious
Net sales $1.67B, down 8% (organic -2%) on category slowdowns and unfavorable price mix.
Clorox enters $1.2B five-year unsecured revolving credit facility, replaces prior agreement
New $1.2B five-year unsecured revolving credit agreement signed March 25, 2025 with JPMorgan, Citi, and Wells Fargo as administrative agents.
Clorox Q2 net sales down 15%; Glad JV to wind down; adjusted EPS falls 28%
Net sales fell 15% to $1.69B; organic sales down 9%; diluted EPS $1.54 (+105%) but adjusted EPS $1.55 (-28% YoY).
Clorox CFO Kevin Jacobsen to Retire April 1; Luc Bellet Named CFO
Kevin Jacobsen, CFO since 2018, to retire effective April 1, 2025, after nearly 30 years at Clorox; will advise until June.
Clorox adds two new directors to board; shareholders re-elect all nominees at 2024 annual meeting
Shareholders elected all 11 director nominees, including new directors Stephen Bratspies and Pierre Breber, at Nov 20 annual meeting.
Clorox Q1 FY2025: net sales +27% to $1.76B; adj. EPS $1.86 vs $0.49 YoY; raised outlook
Diluted EPS rose 371% to $0.80; adjusted EPS of $1.86 (+280% YoY) on strong ops and cyberattack lapping.
Clorox completes divestiture of Better Health VMS business to Piping Rock affiliate
Sale includes Natural Vitality, NeoCell, Rainbow Light, RenewLife brands, related trademarks and licenses.
Clorox Q4 net sales -6% to $1.9B; adjusted EPS +9% to $1.82; divests VMS business
Q4 GAAP diluted EPS $1.73 (+22% YoY); adjusted EPS $1.82 (+9%) vs $1.67.
Clorox Q3 net sales down 5% to $1.81B; adjusted EPS up 13% to $1.71
Net sales fell 5% to $1.81B; organic sales up 2% despite cyberattack disruptions.
Clorox sells Argentina, Uruguay, Paraguay operations to Apex Capital; expects $233M charge
Sale to Apex Capital (Grupo Mariposa) and former Clorox exec Diego Barral; financial terms not disclosed.
Clorox Q2 net sales +16% to $1.99B; adj. EPS $2.16 vs $0.98 YoY; cyber recovery ahead of schedule
Net sales $1.99B, up 16% YoY; organic sales +20% driven by volume rebuild from August cyberattack.
Clorox CEO Linda Rendle to become Board Chair; Shattock to Lead Independent Director
CEO Linda Rendle elected Board Chair effective Jan. 1, 2024; Matthew Shattock becomes Lead Independent Director.
Clorox Q1 net sales down 20% to $1.4B; diluted EPS 17¢ (-75%), adjusted EPS 49¢ (-47%)
Net sales $1.4B, down 20%; organic sales down 18%; volume down 26%.
Clorox warns Q1 net sales down ~25% on cyber attack; sees adjusted EPS loss up to $0.40
Preliminary Q1 FY2024 net sales expected down 28% to 23% YoY; organic sales down 26%–21% vs prior mid-single-digit growth.
Clorox discloses cybersecurity incident causing material Q1 financial impact
Identified unauthorized IT activity on Aug. 14, 2023; took systems offline to contain.
Clorox reports cybersecurity incident causing disruption to IT systems and business operations
Unauthorized activity identified on some IT systems; steps taken to stop and remediate, including taking systems offline.
Clorox Q4 net sales +12% to $2.0B, adjusted EPS $1.67, gross margin +560 bps
Net sales increased 12% to $2.0 billion; organic sales up 14%.
Clorox Group President Rebecca Dunphey resigns effective Aug 11; Dan Dahlgren returns as interim
Rebecca Dunphey, Group President of Care & Connection, resigns effective August 11, 2023.
Clorox amends bylaws to add universal proxy rule requirements and emergency provisions
Bylaws amended effective May 22, 2023, to add procedural requirements for shareholders using SEC's Universal Proxy Rule.
Clorox Q3 FY2023: adj EPS +15%, net sales +6%, raises full-year outlook
Net sales $1.91B (+6% YoY); organic sales +8%; gross margin 41.8% (+590 bps).
Clorox Q2 EPS $0.80 ($0.98 adj.) beats; net sales +1% to $1.72B; gross margin up 320 bps
Net sales $1.72B, +1% vs prior year; organic sales +4% driven by price mix (+14%) offsetting volume decline (-10%).
Clorox shareholders elect all 12 directors, approve say-on-pay, ratify auditor
All 12 director nominees elected; lowest support was Matthew J. Shattock with 84.0M for, 2.3M against.
Clorox Q1 sales down 4% to $1.74B; EPS falls 40%; confirms FY outlook
Diluted EPS of $0.68, down 40% YoY; adjusted EPS $0.93, down 23%.
Q4 net sales flat at $1.8B; organic sales +1%; diluted EPS $0.81 (+4% YoY); adjusted EPS $0.93 (-2%).
Clorox appoints Julia Denman and Stephanie Plaines to board of directors, expanding to 13 members
Julia Denman, Microsoft Corp VP and head of internal audit, and Stephanie Plaines, former Sam's Club CFO for e-commerce, elected to Clorox board effective May 16, 2022.
Clorox redeems $600M 3.05% Senior Notes (Sep 2022) and $500M 3.50% Senior Notes (Dec 2024)
Redemption of $600M 3.05% Senior Notes due Sep 2022 on June 15, 2022 at par plus accrued interest.
Clorox completes $1.1B senior notes offering (4.400% due 2029 and 4.600% due 2032)
$1.1B aggregate: $500M of 4.400% Senior Notes due 2029 and $600M of 4.600% Senior Notes due 2032.
Clorox Q3 FY2022: Net sales +2% to $1.8B; gross margin down 760 bps; adjusted EPS down 19%
Net sales rose 2% to $1.8B; organic sales also up 2% vs flat prior year.
Clorox signs second 12-year, 47 MW VPPA for renewable electricity from Enel Green Power
12-year agreement for 47 MW from Enel Green Power's Oklahoma wind farm starting Jan 2023.
Clorox enters $1.2B five-year revolving credit facility, replaces existing facility
Entered $1,200,000,000 five-year unsecured revolving credit agreement on March 25, 2022.
Clorox Chief Growth Officer Tony Matta departs; Stacey Grier promoted to succeed
Tony Matta, EVP – Chief Growth Officer, leaves Clorox effective March 11, 2022.
Clorox Q2 net sales fall 8%, gross margin drops 1240 bps to 33%, EPS down 72%
Net sales $1.7B, down 8% vs prior year; organic sales -8% reflecting 10-point volume decline.
Clorox amends severance plans and shareholders approve stock plan at annual meeting
Shareholders approved the amended 2005 Stock Incentive Plan with 80.1 million votes for, 3.8 million against.
Clorox Q1 FY2022 net sales fall 6%; EPS down 65% as gross margin drops 1090 bps
Net sales declined 6% to $1.8B; organic sales down 5% compared to 27% growth a year ago.
Clorox Q4 EPS sinks 68%, sales fall 9%; FY margins contract sharply
Q4 diluted EPS $0.81, down 68% YoY; full-year diluted EPS down 24%.
Nina Barton, formerly Executive Vice President and Group President – Care & Connection, was appointed Executive Vice President and Chief Growth & Strategy Officer, effective June 17, 2026.
On May 26, 2026, Linda Rendle, Chair of the Board of Directors (the “Board”) and Chief Executive Officer (“CEO”) of The Clorox Company (the “Company”), asked the Board to initiate a CEO search process, as she has made the decision to step down for health reasons.
On May 11, 2025, the Board of Directors (the “Board”) of The Clorox Company (the “Company”) elected Gina Boswell to the Board, effective May 19, 2025.
On January 23, 2025, Kevin Jacobsen, Executive Vice President – Chief Financial Officer of The Clorox Company (the “Company”), provided notice of his intention to retire from the Company effective April 1, 2025
On January 23, 2025, the Management Development and Compensation Committee (the “MDCC”) of the Board of Directors of the Company appointed Luc Bellet, age 46, to be Executive Vice President – Chief Financial Officer, effective April 1, 2025.
The Company announced that Dan Dahlgren, a long-time Clorox executive who retired last year, will return to the Company to provide interim leadership to the Company’s Care & Connection group.
On July 24, 2023, Rebecca Dunphey, Group President – Care & Connection of The Clorox Company (the “Company”), provided notice of her intention to resign from the Company effective August 11, 2023.
elected Julia (Charter) Denman and Stephanie Plaines to the Board, each effective as of May 16, 2022.
elected Julia (Charter) Denman and Stephanie Plaines to the Board, each effective as of May 16, 2022.
Stacey Grier, currently Senior Vice President – Chief Marketing and Strategy Officer, is being promoted to the role of Executive Vice President – Chief Growth & Strategy Officer, effective March 14, 2022.
Tony Matta, Executive Vice President – Chief Growth Officer of the Company, would be leaving the Company, effective March 11, 2022.
Max materiality 1.00 · Median 0.65 · Most common event earnings